Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF - PubMed (original) (raw)
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
Victoria Emuss et al. Cancer Res. 2005.
Abstract
The protein kinase B-RAF is mutated in approximately 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.
Similar articles
- Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M. Ikenoue T, et al. Cancer Res. 2003 Dec 1;63(23):8132-7. Cancer Res. 2003. PMID: 14678966 - C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA, DeNicola GM, Winter SP, Tuveson DA. Karreth FA, et al. Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017. Mol Cell. 2009. PMID: 19917255 - Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J, Sill H. Zebisch A, et al. Cancer Res. 2006 Apr 1;66(7):3401-8. doi: 10.1158/0008-5472.CAN-05-0115. Cancer Res. 2006. PMID: 16585161 - RAF protein-serine/threonine kinases: structure and regulation.
Roskoski R Jr. Roskoski R Jr. Biochem Biophys Res Commun. 2010 Aug 27;399(3):313-7. doi: 10.1016/j.bbrc.2010.07.092. Epub 2010 Jul 30. Biochem Biophys Res Commun. 2010. PMID: 20674547 Review. - Raf: a strategic target for therapeutic development against cancer.
Beeram M, Patnaik A, Rowinsky EK. Beeram M, et al. J Clin Oncol. 2005 Sep 20;23(27):6771-90. doi: 10.1200/JCO.2005.08.036. J Clin Oncol. 2005. PMID: 16170185 Review.
Cited by
- Pathological and molecular advances in pediatric low-grade astrocytoma.
Rodriguez FJ, Lim KS, Bowers D, Eberhart CG. Rodriguez FJ, et al. Annu Rev Pathol. 2013 Jan 24;8:361-79. doi: 10.1146/annurev-pathol-020712-164009. Epub 2012 Oct 29. Annu Rev Pathol. 2013. PMID: 23121055 Free PMC article. Review. - The role of BRAF V600 mutation in melanoma.
Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. Ascierto PA, et al. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. J Transl Med. 2012. PMID: 22554099 Free PMC article. - How the BRAF V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications.
Bond CE, Whitehall VLJ. Bond CE, et al. Gastroenterol Res Pract. 2018 Nov 26;2018:9250757. doi: 10.1155/2018/9250757. eCollection 2018. Gastroenterol Res Pract. 2018. PMID: 30598662 Free PMC article. Review. - Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
Nucera C, Goldfarb M, Hodin R, Parangi S. Nucera C, et al. Biochim Biophys Acta. 2009 Apr;1795(2):152-61. doi: 10.1016/j.bbcan.2009.01.003. Epub 2009 Jan 31. Biochim Biophys Acta. 2009. PMID: 19356676 Free PMC article. Review. - The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
Nucera C, Lawler J, Hodin R, Parangi S. Nucera C, et al. Oncotarget. 2010 Dec;1(8):751-756. doi: 10.18632/oncotarget.210. Oncotarget. 2010. PMID: 21321384 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous